Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study.

C Polman1, F Barkhof, L Kappos

  • 1Department of Neurology, Free University Medical Center, de Boelelaan 1117, NL-1007 MB Amsterdam, The Netherlands. ch.polman@vumc.nl

Multiple Sclerosis (Houndmills, Basingstoke, England)
|August 21, 2003
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biopharmaceuticals: importance, application, function - a narrative review.

European review for medical and pharmacological sciences·2025
Same author

The Timed Up and Go Test in Patients with Haemophilia: Assessing Reliability, Validity, and Predictive Variables.

Hamostaseologie·2025
Same author

Immunoinflammatory response in periodontal diseases.

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society·2025
Same author

Sexual dysfunction in multiple sclerosis: The impact of different MSISQ-19 cut-offs on prevalence and associated risk factors.

Multiple sclerosis and related disorders·2023
Same author

The Preperitoneal Space in Hernia Repair.

Frontiers in surgery·2022
Same author

Do patients' and referral centers' characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2022

Oral interferon beta-1a (IFNB-1a) did not demonstrate significant benefits for relapsing-remitting multiple sclerosis (RRMS) patients. The oral formulation was found to be safe and well-tolerated, with no notable differences in adverse events compared to placebo.

Area of Science:

  • Neuroimmunology
  • Clinical Neurology
  • Pharmacology

Background:

  • Parenteral interferon beta (IFNB) is a standard treatment for multiple sclerosis (MS).
  • Investigating oral IFNB-1a offers a potentially more convenient administration route.
  • Oral IFNB-1a has not been extensively studied for its efficacy and safety in RRMS.

Purpose of the Study:

  • To evaluate the safety and tolerability of three different doses of oral IFNB-1a.
  • To assess the effects of oral IFNB-1a on MRI lesions in relapsing-remitting MS (RRMS) patients.
  • To compare oral IFNB-1a efficacy against placebo over a six-month period.

Main Methods:

  • A multicenter, double-blind, randomized trial involving RRMS patients.
  • Patients received oral IFNB-1a (0.06, 0.6, or 6 MIU) or placebo every other day for six months.

Related Experiment Videos

  • MRI scans were used to quantify newly active lesions, enhancing lesion volume, and T2 lesion volume.

    • Main Results:

    • No significant differences in the cumulative number of newly active MRI lesions were observed between oral IFNB-1a doses and placebo.
    • Secondary efficacy endpoints showed minimal and inconsistent differences across treatment groups.
    • Oral IFNB-1a was safe and well-tolerated, with comparable adverse event profiles to placebo; no neutralizing antibodies were detected.

    Conclusions:

    • Oral IFNB-1a demonstrated no beneficial effects on MRI lesions or clinical outcomes in RRMS patients.
    • The study found no evidence of systemic biological effects from oral IFNB-1a.
    • Oral IFNB-1a is a safe and well-tolerated treatment option for RRMS, although lacking efficacy.